Skip to main content
Equibles

GDTC · CytoMed Therapeutics Ltd · Metrics

Track GDTC — free

Use GDTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GDTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.87 +0.02 (+2.28%)
Rebalance outlook locked
Market Cap
$10.17M
Shares
11.93M
Volume · Oct 20 8282 Avg daily vol (3M) 81.1K

GDTC metrics

46 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.87
Market cap
$10.17M

Price action

20 metrics
Price change (1W)
+5.0%
Price change (30D)
-12.2%
Price change (3M)
-13.1%
Price change (6M)
-16.5%
Price change (YTD)
-36.2%
Price change (1Y)
-62.8%
Trailing year
Price change (5Y)
—
52-week high
$2.69
52-week low
$0.72
Change from 52-week high
-68.3%
Change from 52-week low
+17.8%
Annualized volatility
93.7%
Annualized volatility (3M)
93.0%
Beta
-0.1
RSI (14D)
45.8
Price vs SMA 50
-4.7%
Price vs SMA 200
-15.0%
Avg volume (3M)
80,993
Relative volume
0.2
Average dollar volume
$77,551

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
11.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.0
reciprocal yield 50.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
-1,227.1%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.55

Growth

11 metrics
Revenue growth YoY
+366.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
-51.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-60.8%
Return on assets
-49.8%
Debt / equity
—
Current ratio
5.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.63M
Total assets
$6.21M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
3
13F filer change QoQ
0
Institutional ownership
0.1%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-27.3%
Holder tenure
3.8
Price vs estimated holder cost
-9.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1873093 CUSIP Y1R80M106 Visit website Investor relations